Quantitative determination of percutaneous absorption of radiolabeled drugs in vitro and in vivo by human skin.
We have measured concentrations of about 30 drugs in the living layers of the skin under conditions which provide data which are applicable in therapeutic treatment. Since the skin is a thin organ and small amounts of drug represent high target concentrations, it is necessary to select a sensitive quantitative method; observation of the kinetics of absorption using radiolabeled drugs is the method of choice. Because of possible hazards--and legal and ethical problems--absorption studies in human skin are commonly performed in vitro. Related in vivo investigations demonstrate the relevance and the limitations of the in vitro experiments. The main hindrance against penetration of drugs is by the horny layer. The barrier-function of this layer--if it is undisturbed--may be described by a multilayer model. The reciprocal function, the reservoir function, is important for the efficiency of topical treatment; it also plays a role in determining the unique pharmacokinetics of drug absorption in the skin and percutaneous resorption. If the horny layer is injured, i.e. in diseased skin, both the barrier and the reservoir functions are disturbed. In consequence, drug concentrations in the skin--and percutaneous resorption--may be greatly enhanced, and topically applied drugs may enter preferentially into diseased areas. The form of application, such as ointment, solution, etc. influences the penetration kinetics in such a specific manner that a specific vehicle for a specific drug should always be postulated. The frequently discussed hazards of side effects due to percutaneous resorption of drugs like corticosteroids are a function of the treated area rather than of its penetration capacity. Thus the indication for local or oral treatment of severe dermatoses should be considered in terms of the affected area. The relatively frequent side effects in the skin itself which originate from unnecessarily high drug concentrations and long term treatment must also be taken into account.
D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000378:metabolism; D001345:Autoradiography; D003899:Desoximetasone / Q000378:metabolism; D006801:Humans; D006854:Hydrocortisone; D066298:In Vitro Techniques; D007700:Kinetics; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D014677:Pharmaceutical Vehicles / Q000494:pharmacology; D011092:Polyethylene Glycols / Q000494:pharmacology; D011868:Radioisotopes; D012869:Skin Absorption / Q000187:drug effects; D014221:Triamcinolone / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D004364:Pharmaceutical Preparations; D014677:Pharmaceutical Vehicles; D011868:Radioisotopes; D014221:Triamcinolone; D011092:Polyethylene Glycols; D003899:Desoximetasone; D006854:Hydrocortisone